Table 1.
Patient demographics and baseline characteristics
|
20 mg BID (n = 4) |
40 mg BID (n = 4) |
60 mg BID (n = 7) |
Total (N = 15) |
|
|---|---|---|---|---|
| Tumor type, n (%) | ||||
| Ovarian a | 1 (25.0) | 1 (25.0) | 4 (57.1) | 6 (40.0) |
| Fallopian a | 1 (25.0) | 1 (25.0) | 1 (14.3) | 3 (20.0) |
| Triple‐negative breast cancer | 2 (50.0) | 2 (50.0) | 2 (28.6) | 6 (40.0) |
| Median age, years (range) | 52.5 (48–62) | 47.0 (32–66) | 49.0 (46–70) | 49.0 (32–70) |
| ECOG status, n (%) | ||||
| 0 | 0 | 1 (25.0) | 1 (14.3) | 2 (13.3) |
| 1 | 4 (100.0) | 3 (75.0) | 6 (85.7) | 13 (86.7) |
| Number of prior lines of therapy, n (%) | ||||
| 1 | 0 | 1 (25.0) | 0 | 1 (6.7) |
| 2 | 1 (25.0) | 2 (50.0) | 0 | 3 (20.0) |
| 3 | 2 (50.0) | 0 | 2 (28.6) | 4 (26.7) |
| ≥4 | 1 (25.0) | 1 (25.0) | 5 (71.4) | 7 (46.7) |
| gBRCA status, n (%) | ||||
| BRCA1 mutation | 0 | 1 (25.0) | 4 (57.1) | 5 (33.3) |
| BRCA2 mutation | 0 | 0 | 2 (28.6) | 2 (13.3) |
| BRCA wild type | 4 (100.0) | 3 (75.0) | 1 (14.3) | 8 (53.3) |
| tBRCA status, n (%) | ||||
| BRCA1 mutation | 0 | 1 (25.0) | 1 (14.3) | 2 (13.3) |
| BRCA2 mutation | 0 | 0 | 1 (14.3) | 1 (6.7) |
| Both BRCA1 and BRCA2 mutation | 0 | 0 | 2 (28.6) | 2 (13.3) |
| BRCA wild type | 1 (25.0) | 1 (25.0) | 1 (14.3) | 3 (20.0) |
| Unknown | 3 (75.0) | 2 (50.0) | 2 (28.6) | 7 (46.7) |
| Median time from initial diagnosis, years (range) | 3.7 (1.0–7.6) | 2.0 (0.4–3.4) | 5.2 (1.4–14.1) | 3.4 (0.4–14.1) |
Abbreviations: BID, twice daily; BRCA, breast cancer susceptibility gene; ECOG, Eastern Cooperative Oncology Group; gBRCA, germline BRCA; tBRCA, tumor BRCA.
a
Included in HGOC population.